Third, important prognostic variables—such as axillary lymph node burden and tumor molecular subtype (e.g., ER, PR, HER2 status)—were not consistently reported or controlled for, limiting our ability to adjust for these factors in the analysis. Here, ERBB2 is linked to neoplasm.